DHL Group has announced the acquisition of CRYOPDP, a leading provider of innovative temperature-controlled logistics solutions for the life sciences and healthcare industries, from Cryoport. This strategic move aims to enhance DHL’s capabilities in managing complex supply chains for critical and sensitive shipments, including clinical trials, cell and gene therapies, and personalized medicine. With CRYOPDP’s extensive global network and expertise in temperature-controlled logistics, DHL will expand its healthcare logistics footprint and strengthen its position in the life sciences sector.
Also Read: E2open Enhances Global Trade Compliance with AI Innovations
“This acquisition reflects our continued commitment to supporting the life sciences and healthcare industry with specialized logistics solutions,” said Katja Busch, Chief Commercial Officer at DHL Group. The acquisition is expected to provide DHL’s customers with a seamless, end-to-end cold chain solution, leveraging CRYOPDP’s deep industry knowledge and DHL’s extensive global reach. This move aligns with DHL’s strategy to expand its healthcare logistics portfolio, delivering reliable, compliant, and innovative solutions for the evolving needs of the healthcare sector.